supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months

You'll see supplies of the direct thrombin inhibitor lepirudin (Refludan) dwindle over the next few months.

It's not a drug shortage. Lepirudin is being discontinued by the manufacturer for business reasons...not safety concerns.

This leaves just one first-line agent for preventing and treating thrombosis in patients with heparin-induced thrombocytopenia (HIT).

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote